• Product NameRecombinant Murine Interleukin-13
• Host SpeciesEscherichia coli.
• Purification> 97 % by SDS-PAGE and HPLC analyses.
• Biological ActivityFully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human TF-1 cells is less than 4 ng/ml, corresponding to a specific activity of > 2.5 x10⁵ IU/mg.
• EndotoxinLess than 1 EU/ug of rMuIL-13 as determined by LAL method.
• UniprotP20109
• Gene ID16163
• Calculated MW Approximately 12.3 kDa, a single non-glycosylated polypeptide chain containing 111 amino acids.
• Target Sequence MPVPRSVSLP LTLKELIEEL SNITQDQTPL CNGSMVWSVD LAAGGFCVAL DSLTNISNCN AIYRTQRILH GLCNRKAPTT VSSLPDTKIE VAHFITKLLS YTKQLFRHGP F
• Formulation Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4.
• Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 ˚C as supplied.- 1 month, 2 to 8 ˚C under sterile conditions after reconstitution.- 3 months, -20 to -70 ˚C under sterile conditions after reconstitution.

Murine Interleukin-13 (IL-13) is expressed by the IL13 gene located on the chromosome 11 and secreted by many cell types, especially T helper type 2 (Th2) cells. Targeted deletion of IL-13 in mice resulted in impaired Th2 cell development and indicated an important role for IL-13 in the expulsion of gastrointestinal parasites. IL-13 has been implicated as a key factor in asthma, allergy, atopy and inflammatory response, establishing the protein as a valuable therapeutic target. Human, mouse and rat IL-3 share low homology, but have cross species activity.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting